A Phase 1, Open-label, Multi-part Positron Emission Tomography (PET) Imaging Study to Evaluate the Biodistribution and Radiation Dosimetry of the Monoacylglycerol Lipase (MGLL) PET Ligand [18F]T-401 and to Evaluate Fatty Acid Amide Hydrolase (FAAH) and MGLL Enzyme Availability in the Central Nervous System Using [11C]MK-3168 and [18F]T-401 PET Ligands Before and After Oral Administration of Single and Multiple Doses of CC-97489 in Healthy Adult Subjects

The purpose of this study is to evaluate enzyme availability in the central nervous system before and after CC-97489 administration in healthy participants

Start Date24 Sep 2021

Sponsor / Collaborator

Celgene Corp.

NCT04404712 / TerminatedEarly Phase 1IIT

FAAH Availability in Psychiatric Disorders: A PET Study

The aim of the present study is to examine Fatty Acid Amide Hydrolase (FAAH) availability in humans, including healthy individuals and across a spectrum of psychiatric disorders in which alterations in the endocannabinoid system are observed.

Start Date23 Sep 2020

Sponsor / Collaborator

Yale University

NCT02169973 / CompletedPhase 1

An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

The purpose of the study is to measure the uptake, distribution, and clearance of 11C-MK-3168 by Positron Emission Tomography (PET) scan and to model the tissue specific kinetics of 11C-MK-3168 with the appropriate input function in human brain in Part A; to measure blocking of retention of 11C-MK-3168 at the estimated time to maximum plasma concentration after dosing (tmax) following each single oral doses of JNJ-42165279 and model the exposure/enzyme interaction of JNJ-42165279 in Part B; to measure the saturation of enzyme inhibition in the brain at steady state plasma concentrations of JNJ-42165279 (on Day 8) after 7 once-daily doses of JNJ-42165279 by conducting PET studies with 11C-MK-3168 at trough plasma concentrations on Day 2 in Part C.

Start Date01 Feb 2014

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with MK-3168

100 Translational Medicine associated with MK-3168

100 Patents (Medical) associated with MK-3168

Literatures (Medical) associated with MK-3168

01 Jul 2018·Clinical and Translational Science

Fatty Acid Amide Hydrolase Inhibition by JNJ‐42165279: A Multiple‐Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers

Article

Author: Celen, Sofie ; Pemberton, Darrel J. ; Zannikos, Peter ; Palmer, James A. ; van den Boer, Maarten ; van Laere, Koen ; Bormans, Guy ; Schmidt, Mark E. ; Rassnick, Stef ; Postnov, Andrey ; de Hoon, Jan ; van der Ark, Peter ; van Hecken, Anne

AbstractInhibition of fatty acid amide hydrolase (FAAH) potentiates endocannabinoid activity and is hypothesized to have therapeutic potential for mood and anxiety disorders and pain. The clinical profile of JNJ‐42165279, an oral selective FAAH inhibitor, was assessed by investigating the pharmacokinetics, pharmacodynamics, safety, and binding to FAAH in the brain of healthy human volunteers. Concentrations of JNJ‐42165279 (plasma, cerebrospinal fluid (CSF), urine) and fatty acid amides (FAA; plasma, CSF), and FAAH activity in leukocytes was determined in a phase I multiple ascending dose study. A positron emission tomography study with the FAAH tracer [11C]MK3168 was conducted to determine brain FAAH occupancy after single and multiple doses of JNJ‐42165279. JNJ‐42165279 administration resulted in an increase in plasma and CSF FAA. Significant blocking of brain FAAH binding of [11C]MK3168 was observed after pretreatment with JNJ‐42165279. JNJ‐42165279 produces potent central and peripheral FAAH inhibition. Saturation of brain FAAH occupancy occurred with doses ≥10 mg of JNJ‐42165279. No safety concerns were identified.

13 Jun 2013·ACS Medicinal Chemistry LettersQ3 · MEDICINE

Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase

Q3 · MEDICINE

Article

Author: Abbadie, Catherine ; Guo, Yan ; Jin, Hong ; Sanabria, Sandra ; Chobanian, Harry ; Posavec, Diane ; Salituro, Gino ; Chioda, Marc ; Chang, Linda ; Shiao, Lin-Lin ; Madeira, Maria ; Hamill, Terence G ; DeVita, Robert J ; Hong, Qingmei ; Holahan, Marie ; Jochnowitz, Nina ; Alexander, Jessica ; Rosenbach, Mark ; Lin, Linus S ; Purcell, Mona ; Terebetski, Jenna L ; Powell, Joyce ; Hajdu, Richard ; O'Malley, Stacey ; Chen, Tsing-Bau ; Karanam, Bindhu ; Nargund, Ravi P ; Bakshi, Raman ; Cook, Jacquelynn ; Sullivan, Kathleen A ; Mandala, Suzanne ; Dellureficio, James ; Williams, David ; Liu, Ping ; Riffel, Kerry ; Miller, Patricia ; Hargreaves, Richard ; Williams, Mangay ; Leone, Joseph F ; Zeng, Zhizhen ; Joshi, Aniket ; Li, Wenping ; Xu, Ling ; Fung, Selena

We report herein the discovery of a fatty acid amide hydrolase (FAAH) positron emission tomography (PET) tracer. Starting from a pyrazole lead, medicinal chemistry efforts directed toward reducing lipophilicity led to the synthesis of a series of imidazole analogues. Compound 6 was chosen for further profiling due to its appropriate physical chemical properties and excellent FAAH inhibition potency across species. [(11)C]-6 (MK-3168) exhibited good brain uptake and FAAH-specific signal in rhesus monkeys and is a suitable PET tracer for imaging FAAH in the brain.

100 Deals associated with MK-3168

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alcohol Use Disorder	Phase 1	US	Yale University	23 Sep 2020
Behavioural disorders	Phase 1	US	Yale University	23 Sep 2020
Psychotic Disorders	Phase 1	US	Yale University	23 Sep 2020
Stress Disorders, Post-Traumatic	Phase 1	US	Yale University	23 Sep 2020
Diagnostic agents	Discovery	-	Merck Sharp & Dohme Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis